Real-World Clinical Outcomes of Teclistamab and Talquetamab in Relapsed/Refractory Multiple Myeloma (RRMM): A UK Single-Centre Experience

被引：0
作者：
Feixas, Pablo Tenorio [1 ]
Cox, Catrin [1 ]
Peer, Xavier [1 ]
Cuthill, Kirsty [1 ]
Benjamin, Reuben [2 ]
Gunawan, Arief [2 ]
Cuadrado, Maria [1 ]
de Farias, Madson Correia [1 ]
Jones, John [1 ]
Shin, Jin-Sup [1 ]
Batool, Asma [1 ]
Bowcock, Stella [1 ]
Omer, Musab [1 ]
Tawde, Prachi [1 ]
Bailey, Katharine [1 ]
机构：
[1] Kings Coll Hosp NHS Fdn Trust, London, England
[2] Kings Coll Hosp London, London, England
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-087
引用
收藏
页码：S92 / S92
页数：1
相关论文
共 50 条
  • [41] A real-world observational study of belantamab mafodotin (belamaf) as a treatment for relapsed/refractory multiple myeloma (RRMM)
    Cavo, Michele
    Delforge, Michel
    Dimopoulos, Meletios
    Escalante, Fernando
    Hultcrantz, Malin
    Kleinman, David
    Lee, Hans
    Vij, Ravi
    Kotowsky, Nirali
    Camadoo-O'Byrne, Leena
    Bitetti, Jacopo
    D'Estrube, Tim
    Fry, Mark
    Vossen, Carla
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S166 - S167
  • [42] Real-world Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): IONA-MM First Interim Analysis
    Thomas, Martin
    Meral, Beksac
    Michele, Cavo
    Wolfgang, Knauf
    Nobuhiro, Tsukuda
    Christina, Tekle
    Zhenming, Zhao
    Manasanch, Elisabet E.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S27 - S27
  • [43] Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis
    Gaballa, Mahmoud R.
    Martin, Thomas G.
    Tsukada, Nobuhiro
    Suzuki, Kazuhito
    Iriuchishima, Hirono
    Chalayer, Emilie
    Camus, Vincent
    Pena, Maria Magdalena Alcala
    Furlan, Anna
    Hubmann, Max Christian Georg
    Knauf, Wolfgang Ulrich
    Tekle, Christina
    Minasyan, Ani
    Qiu, Chunfu
    Beksac, Meral
    BLOOD, 2024, 144 : 24115 - 24116
  • [44] Real-World Study of Treatment Patterns in Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM) in the US
    Wang, Peter Feng
    Sansbury, Leah
    DerSarkissian, Maral
    Ferrante, Shannon
    Bhak, Rachel
    Gorsh, Boris
    Zichlin, Miriam L.
    Yee, Christopher W.
    Boytsov, Natalie
    Khanal, Anamika
    Paka, Prani
    Noman, Ahmed
    Duh, Mei Sheng
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S423 - S423
  • [45] Real-world experience with isatuximab in patients with relapsed and/or refractory multiple myeloma (RRMM): IONA-MM first interim analysis
    Martin, Thomas
    Beksac, Meral
    Cavo, Michele
    Knauf, Wolfgang
    Tsukada, Nobuhiro
    Tekle, Christina
    Zhao, Zhenming
    Manasanch, Elisabet
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S178 - S178
  • [46] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience
    Hultcrantz, Malin
    Orozco, Jennifer
    Peterson, Tim J.
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Lu, Sydney X.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Maclachlan, Kylee H.
    Chung, David J.
    Landau, Heather J.
    Shah, Gunjan L.
    Lahoud, Oscar B.
    Scordo, Michael
    Landgren, Ola
    Giralt, Sergio
    Lesokhin, Alexander
    BLOOD, 2021, 138
  • [47] Real World Outcomes with Elotuzumab-Based Therapies for Patients with Relapsed Refractory Multiple Myeloma (RRMM): A Mayo Clinic Experience
    Parrondo, Ricardo
    Das, Saurav
    Hodge, David
    Sledge, Hanna
    Bergsagel, P. Leif
    Fonseca, Rafael
    Leung, Nelson
    Kapoor, Prashant
    Gertz, Morie
    Buadi, Francis
    Dispenzieri, Angela
    Elliott, Jamie
    Fernandez, Andre
    Chanan-Khan, Asher
    Roy, Vivek
    Ailawadhi, Sikander
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S272 - S273
  • [48] Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd
    Chari, Ajai
    Richardson, Paul G.
    Romanus, Dorothy
    Dimopoulos, Meletios A.
    Sonneveld, Pieter
    Terpos, Evangelos
    Hajek, Roman
    Raju, Aditya
    Palumbo, Antonio
    Cain, Lauren E.
    Blazer, Marlo
    Huang, Hui
    Farrelly, Eileen
    Ailawadhi, Sikander
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (04) : 421 - 433
  • [49] Real-World Outcomes in Patients With Relapsed-Refractory Multiple Myeloma (RRMM) With Prior Proteasome Inhibitor and Lenalidomide Exposure in Sweden
    Luong, Vincent
    Kashif, Muhammad
    Uttervall, Katarina
    Bohlin, Anna
    Fernstrom, Annette Oster
    Qu, Ying
    Lee, Seina
    Mendes, Joao
    Van Hoorenbeeck, Sandra
    Franck, Eva Hellqvist
    He, Jianming
    Alici, Evren
    Lund, Johan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S269 - S270
  • [50] Real-world Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): IONA-MM First Interim Analysis
    Schwarzer, A.
    Schulte, C.
    Fries, S.
    Cavo, M.
    Tsukada, N.
    Tekle, C.
    Manasanch, E. E.
    Knauf, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 316 - 316
12345